Dry Eye Medication Market 2021 - By Prescription Type (OTC Drugs, Prescription Drugs) By Drug Variation (Branded, Generic) By Type Of Product (Aqueous, Evaporative, Aqueous And Evaporative) By Distribution Channel (Hospital Pharmacies, Eye Health Clinics, Retail Pharmacies, Online Pharmacies) By Delivery System (Liquid, Gel, Ointment) And By Region, Opportunities And Strategies – Global Forecast To 2030

Acne Drugs Market Definition

Acne drugs refer to medications that aid in the treatment of acne scarring, blackheads, whiteheads, and other more severe types of the condition. It functions either by treating bacterial infections or by lowering edoema and oil production. Usually, it takes four to eight weeks before prescription acne medications start to work. Your acne might not go away completely for several months or even years. The main types of acne drugs are inflammatory acne drugs and non-inflammatory acne drugs. Inflammatory acne drugs refer to the drugs that are used to treat inflammatory acne problems such as mild to moderate inflammatory acne. The various therapeutic classes include retinoids, antibiotics, salicylic acid, and benzoyl peroxide that are used by various end users such as hospitals and clinics, pharmacies and drug stores, and ambulatory surgical centers. The global acne drugs market is segmented - 1) By Type: Inflammatory Acne Drugs, Non-Inflammatory Acne Drugs 2) By End User: Hospitals & Clinics, Pharmacies & Drug Stores, Ambulatory Surgical Centres 3) By Therapeutic Class: Retinoids, Antibiotics, Salicylic Acid, Benzoyl Peroxide The global acne drugs market size will grow from $5.44 billion in 2022 to $5.74 billion in 2023 at a compound annual growth rate (CAGR) of 5.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the global acne drugs market size is expected to grow to $6.90 billion in 2027 at a CAGR of 4.7%. An increase in the disposable income of people is one of the major drivers in the acne drug market. An increase in disposable income is usually due to an improved economy leading to increased wages and salaries and boosting healthcare expenditure. According to the Office For National Statistics (UK), in 2020, the average household disposable income in the UK was £30,800 ($37,830), an increase of 2.3% from 2019. The rise in disposable income and increased expenditure on facial care products is expected to continue, thereby driving the market in the forecast period. Major players in the acne drugs market are Allergan PLC., Galderma S.A., Valeant Pharmaceutical International Inc., Teva Pharmaceutical Industries Ltd., Johnson & Johnson Services Inc., GlaxoSmithKline PLC., Bayer AG, Stiefel Laboratories Inc., Ranbaxy Laboratories Limited, Pfizer Inc., Sun Pharmaceutical Industries Limited, Mayne Pharma Group Limited, Mylan N.V., Cipher, Daiichi Sankyo Company, Ltd., Guthy-Renker LLC., Medicis Pharmaceutical Corporation, Foamix Pharmaceuticals, BioPharmX, In, Roche Holding AG, F. Hoffmann-la Roche Ltd., Anterios Inc., AndroScience, Oculus Innovative Sciences, Aqua Pharmaceuticals, Skinvisible Pharmaceuticals and Prestium Pharma Inc. Acne drugs are a major problem worldwide, close to 90% of people suffer from some sort of acne drug. In America alone, close to 12 million people suffer from a severe acne drug problem, that can lead to scarring of the skin if left untreated, as a result, many people purchase Acne drug care drugs and products. The presence of alternatives for acne drug treatment is one of the restraints on the acne drug market. Due to the availability of multiple alternatives, patients tend to choose one amongst many options based on price, side effects, duration, and many more. This increases the competition and hence, the competition cuts down a significant portion of business for the acne drugs market. For example, some of the alternatives for acne drug treatment apart from acne drugs are Ayurveda, home remedies, laser and photodynamic therapy, and extraction of whiteheads and blackheads using special tools like needles and forceps. Combination therapy is the latest trend in the acne drug market. Combination therapy is the process of combining two drugs with different mechanisms of action, such combinations of medication have better efficacy and adherence when compared with monotherapy (the use of only a single drug by itself). The combination of a topical retinoid drug, which unclogs the pores, along with an antimicrobial drug, which is used to treat an infection is being used to treat acne drugs. Example of combination therapy includes Epiduo, Acanya, Ziana, and Benzamycin produced by Galderma, Allergan, Medicis, and Atrix respectively. The stringent regulations concerning the usage of drugs to treat Acne Drugs have an impact on the acne drug market. The regulations have become more stringent due to the various side effects and adverse events caused during treatment. In India, the Central Drugs Standard Control Organization (CDSCO) has issued a warning regarding the safety guidelines concerning the use of the oral drug, isotretinoin. The CDSCO has directed the states and union territories’ drug controllers to check the labelling of isotretinoin drugs and make end users aware of the serious birth defects the drug may cause. Further, the Subject Expert Committee (SEC) for Dermatology and Allergy has recommended that the drug should be sold only under the prescription of a dermatologist, manufacturers should provide a package insert in local languages, and retail pharmacies should maintain the details of retail sale of the drug. Hence, these strict guidelines and regulations would impact the growth of the acne drug market. In December 2021, Sanofi S.A., a France based pharmaceutical and healthcare company specialising in drug development and commercialization, acquired Origimm Biotechnology GmbH for an undisclosed amount. Through this acquisition, Sanofi increases its vaccine R&D pipeline, skin microbiome and skin immunology expertise, and treatment options for acne disease. And the product will reach the rest of Europe. Origimm Biotechnology GmbH is an Austria based pharmaceutical company pioneering in the identification of pathogenic skin microbiome components and skin disease-causing bacterial antigens. North America was the largest region in the acne drugs market in 2022. The Middle East is expected to be the largest growing region in the global acne drugs market during the forecast period. The regions covered in the global acne drugs market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the acne drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The acne drugs market consists of sales of retinoids, antibiotics, and diapsone. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The acne drugs market research report is one of a series of new reports from The Business Research Company that provides acne drugs market statistics, including acne drugs industry global market size, regional shares, competitors with an acne drugs market share, detailed acne drugs market segments, market trends and opportunities, and any further data you may need to thrive in the acne drugs industry. This acne drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Dry eye medication refers to the drugs or medication that is used to treat dry eye by increasing your eye moisture. A multifactorial condition of the tears and ocular surface known as dry eye causes symptoms such as pain, blurred vision, and tear film instability, as well as the possibility of ocular surface injury. The main types of dry eye medication are aqueous dry eye syndrome and evaporative dry eye syndrome. Dry eye syndrome is a frequent problem that arises when the tears aren't able to keep the eyes lubricated enough. Tears may be insufficient and unstable for a variety of causes. The different types of products include liquid drops, gel, liquid wipes, and eye ointment and are used by hospital pharmacies, eye health clinics, retail pharmacies, and online pharmacies. The global dry eye medication market is segmented - 1) By Type: Aqueous dry eye syndrome, Evaporative dry eye syndrome 2) By end-user: Hospital Pharmacies, Eye Health Clinics, Retail Pharmacies, Online Pharmacies 3) By Product Type: Liquid Drops, Gel, Liquid Wipes, Eye Ointment The global dry eye medication market size will grow from $8.67 billion in 2022 to $9.62 billion in 2023 at a compound annual growth rate (CAGR) of 11.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the global dry eye medication is expected to grow to $13.99 billion in 2027 at a CAGR of 9.8%. The increased number of cases of dry eye disease results in an increased demand for its treatment. Factors such as aging, lack of vitamin A, wearing lenses, eye surgeries, direct contact with dry wind or smoke, and exposing one’s eyes to screens for a long duration increase the occurrence of the dry eye more likely. For example, a survey conducted by the American Academy of Ophthalmology reported that in the USA, nearly 3.2 million women and 1.68 million men, over the age of 50 were affected by dry eye syndrome. Similarly, a study conducted by the Indian Journal of Ophthalmology indicated a 32% prevalence of dry eye disease in the Northern part of India. the rising prevalence of the disease would increase the demand for its treatment and ultimately facilitate the growth of the dry eye medication market. Major players in the dry eye medication market are Novartis, Allergan, Otsuka, Santen Pharmaceutical, Auven Therapeutics, Akorn, Valent Pharmaceuticals, Johnson and Johnson Vision, Alcon and Bausch & Lomb. The market for dry eye medication market is restricted by the long approval process that is undertaken before any drug is approved by the concerned authority. The standard protocol for testing any new drug demands a series of tests and trials including laboratory tests, animal model tests, and clinical trials. Most drugs fail during clinical trials and only a small percent of them successfully move forward. The cumbersome process of obtaining approvals takes a longer duration of time and restricts the growth of this market. For example, in 2020, Eysuvis, a drug that addresses the short-term treatment needs of patients living with dry eye disease, was approved by the Food and Drug Administration (FDA) after its safety and effectiveness were assessed on more than 2900 patients with the disease in different clinical trials. Similarly, Kissei Pharmaceutical announced to discontinue the development of the KCT-0809 drug after it failed to pass the 3rd phase of clinical trials. Treatment for dry eye disease improved with the incorporation of modern techniques that helped invent advanced hyaluronic acid-based lubricants and lipid emulsions. This technology replaces artificial tears that include isotonic sodium chloride and provides long-lasting lubrication on the surface of the eye. For instance, Allergan, a global pharmaceutical company, launched Refresh Repair Lubricant Eye Drops which are designed to repair and protect the eyes from dry eye disease and improve the clarity of vision and are formulated with carboxymethylcellulose (CMC), hyaluronic acid, and osmoprotectants. These components maintain the health of the ocular surface and safeguard epithelial cells. Advances in technology will have a positive effect on the dry eye medication market. The dry eye medication market is strictly regulated by government agencies such as USFDA (Food and Drug Administration), the European Medicines Agency (EMA), and others. For instance, in the USA, FDA evaluates and approves the drugs meant for dry eye treatment. According to Section 201(g) of the FDA and CFR (Code of federal regulations) act, the licenses are granted to drug manufacturing companies allowing them to sell only those drugs that are safe and clinically effective. FDA demands several tests and several clinical trial rounds before granting such approvals. For example, FDA approved Kala Pharmaceuticals’ eye-related drug called INVELTYS. In July 2022, Alcon, a Switzerland-based ophthalmology company acquired Eysuvis pharmaceutical eye drops from Kala Pharmaceuticals for a deal amount of $60 million. Through this acquisition, Alcon acquires Inveltys treatment of post-operative inflammation and pain following ocular surgery and expands its portfolio. Kala Pharmaceuticals is a US-based pharmacuetical company operating in drug eye medication. North America was the largest region in the dry eye medication market in 2022. Middle East is expected to be the fastest-growing region in the global dry eye medication market share during the forecast period. The regions covered in the global dry eye medication market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the dry eye medication market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The dry eye medication market consists of sales of polyethylene glycol, polyvinyl alcohol, propylene glycol, carboxymethylcellulose, povidone, glycerine, and mineral oil. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The dry eye medication market research report is one of a series of new reports from The Business Research Company that provides dry eye medication market statistics, including dry eye medication industry global market size, regional shares, competitors with a dry eye medication market share, detailed dry eye medication market segments, market trends and opportunities, and any further data you may need to thrive in the dry eye medication industry. This dry eye medication market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Medical and diagnostic laboratory services are services that provide diagnostics tests for various diseases. The tests are used for detecting if the person has encountered the disease. Medical and diagnostic laboratory services makes it possible to deliver prompt, affordable, and high-quality diagnostic services in secure settings. The main types of medical and diagnostic laboratory services are diagnostic imaging centres and medical laboratory services. A diagnostic imaging center is a service provider that offers technical or comprehensive diagnostic imaging services. The different expenditure types include public and private that are used in various applications such as cardiology, oncology, neurology, orthopedics, gastroenterology, gynecology, and others. The services are used by males and females. The global medical and diagnostic laboratory services market is segmented - 1) By Type: Diagnostic Imaging Centers, Medical Laboratory Services 2) By Application: Cardiology, Oncology, Neurology, Orthopedics, Gastroenterology, Gynecology, Other Applications 3) By End User Gender: Male, Female 4) By Type of Expenditure: Public, Private Subsegments Covered: Computer Tomography (CT-Scan) Centers, Medical Radiological Laboratories, Dental or Medical X-Ray Laboratories, Ultrasound Imaging Centers, Magnetic Resonance Imaging (MRI) Centers The global medical and diagnostic laboratory services market grew from $169.87 billion in 2022 to $183.84 billion in 2023 at a compound annual growth rate (CAGR) of 8.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The medical and diagnostic laboratory services market is expected to grow to $240.86 billion in 2027 at a CAGR of 7.0%. The rise in sedentary jobs, busy lifestyles, and changing consumer preferences are affecting the disease profile of the world population, especially non-communicable diseases such as cancer, diabetes, and cardiovascular diseases. Long working hours, less physical activity, and unhealthy eating and drinking habits are major causes of chronic diseases such as diabetes. According to the World Health Organization, chronic disease prevalence rose by 57% globally, in 2020. Tests to diagnose these diseases include HbA1c tests for monitoring diabetes, biopsies, tumor marker tests, bone scans, MRI and CT scans for diagnosis of various cancers, electrocardiograms, chest X-rays, cardiac CT scans, and stress tests for detection of cardiovascular diseases. The increase in the prevalence of lifestyle diseases will increase the demand for tests to diagnose these diseases and thus will drive the medical and diagnostic laboratory services market during the forecast period. Major companies in the medical and diagnostic laboratory services market include Laboratory Corporation of America, Eurofins, Quest Diagnostics Incorporated, Sonic Healthcare Limited, Kaiser Permanente, RadNet, OPKO Health, Myriad Genetics, Charles River Laboratories, Inc., and NeoGenomics Laboratories, Inc. The medical and diagnostic laboratory services market is expected to limit by the rising prevalence of self-care diagnostic equipment. These tools can be used by patients without assistance from medical personnel, to diagnose particular disabilities or disorders. Common self-care diagnostic devices include glucose monitoring devices, blood pressure monitoring devices, sleep apnea monitors and temperature monitors. The ease of use of self-care devices has increased demand for them during the last decade and is expected to increase it further during the forecast period. Some virtual applications are also aiding in the diagnosis of certain health conditions. For instance, iPhone is working on an IOS accessory called Cue, which can be used as a home diagnostic kit. Self-care diagnostics is expected to have a negative impact on the traditional medical and diagnostic laboratory services market during the forecast period by reducing the need for laboratory testing for some basic tests. Medical and diagnostic laboratories are using biomarkers to measure health parameters associated with individual wellness. The health and well-being of individuals can be measured by using biomarkers to assess factors behind sleep disorders and symptoms of stress. Biomarkers such as cortisol, testosterone, and secretory IgA can indicate changes in the immune system relating to physical and mental conditions. This can be used by physicians to know the causative factors behind such conditions. This is a premium service primarily targeted at wealthy individuals and senior employees of corporations. North America was the largest region in the medical and diagnostic laboratory services market in 2022. Asia-Pacific was the second largest region in the medical and diagnostic laboratory services market. The regions covered in the medical and diagnostic laboratory services market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the medical and diagnostic laboratory services market are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, and Vietnam. The medical and diagnostic laboratory services market includes revenues earned by entities by providing diagnostic services such as diagnostic laboratory services, X-ray, CT scan, and Mammography. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The medical and diagnostic laboratory services market research report is one of a series of new reports from The Business Research Company that provides medical and diagnostic laboratory services market statistics, including medical and diagnostic laboratory services industry global market size, regional shares, competitors with a medical and diagnostic laboratory services market share, detailed medical and diagnostic laboratory services market segments, market trends and opportunities, and any further data you may need to thrive in the medical and diagnostic laboratory services industry. This medical and diagnostic laboratory services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Medical feed additives are various types of products used in animal nutrition to improve the nutritional content and quality of feed, or to improve the health and performance of animals. They help improve the nutritional content and quality of feed, resulting in higher productivity and disease prevention. The main types of medical feed additives are antioxidants, antibiotics, probiotics, prebiotics, enzymes, and amino acids. The antioxidants refer to the feed additives that are fed to the animals for nutrition. The different mixtures include supplements, concentrates, premixed feeds, and base mixes. The various classes include typing a, type b, and type c. These are used by different livestock, such as ruminants, poultry, swine, and aquaculture. The global medical feed additives market is segmented - 1) By Type: Antioxidants, Antibiotics, Probiotics And Prebiotics, Enzymes, Amino Acids 2) By Livestock: Ruminants, Poultry, Swine, Aquaculture 3) By Mixture Type: Supplements, Concentrates, Premix Feeds, Base Mixes 4) By Class type: Type A, Type B, Type C The global medical feed additives market size will grow from $14.38 billion in 2022 to $15.6 billion in 2023 at a compound annual growth rate (CAGR) of 8.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the global medical feed additives is expected to grow to $20.75 billion in 2027 at a CAGR of 7.4%. An increase in the prevalence of diseases among animals is driving the growth of the medicated feed additives market. According to estimates from a report by the Animal and Plant Health Agency, a total of 3289 new TB herd incidents were detected in England. A new herd incident is a case of bovine TB that occurs as a result of a herd or individual animal test performed in an officially TB-free (OTF) herd during the study period. Bovine tuberculosis is a chronic disease that usually affects animals such as cattle, but it can affect all mammals, causing illness, coughing, and eventual death. Moreover, according to the reports, the herd incidence rate in England for the 12 months to September 2020 was 9.4. The additives help prevent animals from diseases alongside increasing the nutrition level of the feed, thereby increasing demand for feed additives. Major players in the medical feed additives market report are Zoetis Inc., Cargill, Incorporated, CHS Inc., Purina Animal Nutrition, Archer Daniels Midland Company, Adisseo France Sas, Alltech Inc., Hipro Animal Nutrition, BASF SE, Biostadt India Limited. The overuse and inappropriate use of antibiotics in medical feed additives impacts the health of individuals consuming animal meat or other related products. Moreover, the health of the animal consuming the feed may also be adversely affected by the antibiotics added to the feed as the excess additive reduces the natural immunity of the animal and increases the susceptibility of the livestock to infections. For instance, in July 2020, the Ministry of Agriculture and Rural Affairs in China, under Announcement No. 194, banned the production of commercial feed with medicated feed additives (excluding traditional Chinese medicine) for growth-promoting purposes. The negative effects of additives on human health caused by overuse of feed additives in animals will restrain the growth of the medical feed additives market. Companies in the medical feed additives market are introducing new feed medicated additives formed as a result of a combination of two or more medicated feed additives. More than 70% of manufacturers are now using more than one feed additive in animal feed to increase the efficiency of the product. For instance, Zoetis, a global health company, got approval for its Cyden and Lincomix combination feed additive from the FDA (Food and Drug Administration) and it is proposed to be used as a medicated feed additive for poultry. Also, the FDA-approved combination of Zoetis’ feed additives ACTOGAIN 45 (ractopamine hydrochloride) and ENGINE (ractopamine hydrochloride) produces more lean muscle and less fat while optimising feed efficiency. The medical feed additives market is regulated by government agencies that lay down regulations to be followed by all manufacturers of veterinary medicines. For instance, the Veterinary Medicines Regulations (VMR) 2013 make provision for the authorization, manufacturing, and classification of veterinary products, including medicated feed additives. Schedule 5 under EU guidelines covers medicated feeding stuff and specified feed additives, which specify guidance to both manufacturers and suppliers of veterinary medicines for incorporating them into animal feed, as well as to veterinary surgeons, animal keepers, and other members involved in the use of veterinary medicines and SFAs(Specified Feed Additives)in animal feeding stuff. In June 2022, Cargill, Inc., a US-based food and agriculture company, acquired DelaconBiotechnik GmbH for an undisclosed amount. The acquisition combines Delacon's innovative know-how and market experience with Cargill's extensive global network and deep expertise in animal nutrition technologies. Phytogenic feed additives are a category that utilizes a variety of herbs, plants, and their extracts, such as essential oils, to enhance livestock and aquaculture performance, promote animal health, and enhance Cargill’s feed additive research capabilities. DelaconBiotechnik GmbH is an Austria-based feed additive company pioneering in plant-based phytogenic additives to improve livestock and aquaculture performance and promote animal health. North America was the largest region in the medical feed additives market in 2022. Asia-Pacific was the second-largest region in the global medical feed additives market share. The regions covered in the medical feed additives industry report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the medical feed additives market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, and USA. The medical feed additives market consists of sales of digestibility enhancers, coccidiostats and histomonostats, antimicrobials, and growth hormones. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The medical feed additives market research report is one of a series of new reports from The Business Research Company that provides medical feed additives market statistics, including medical feed additives industry global market size, regional shares, competitors with medical feed additives market share, detailed medical feed additives market segments, medical feed additives market trends and opportunities, and any further data you may need to thrive in the medical feed additives industry. This medical feed additives market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Medication adherence are the systems that helps to check if a person follows medication recommended by a healthcare provider, whether patients take their medications as prescribed, as well as whether they continue to take a prescribed medication. Medication adherence hardware and software help medical personnel with the patient’s intake to prescribed medication to reduce cases of worsening disease and deaths and decrease healthcare costs. The main types of medication adherence are hardware-centric and software-centric. Medication adherence products that are software-centric are a collection of programmes or applications which monitor, record, and notify the individual and his or her caregiver about their medication compliance. The different medications include cardiovascular, central nervous system, diabetes, oncology, respiratory, gastrointestinal, rheumatology, others and are used in various applications such as hospital, retail pharmacies, long-term care facilities, mail-order pharmacies. The global medication adherence market is segmented - 1) By Type: Hardware Centric, Software Centric 2) By Medication: Cardiovascular, Central Nervous System, Diabetes, Oncology, Respiratory, Gastrointestinal, Rheumatology, Other Medications 3) By Application: Hospital, Retail Pharmacies, Long-Term Care Facilities, Mail-Order Pharmacies The global medication adherence market size will grow from $3.18 billion in 2022 to $3.58 billion in 2023 at a compound annual growth rate (CAGR) of 12.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The size of the global medication adherence market is expected to grow to $5.36 billion in 2027 at a CAGR of 10.6%. The increasing requirement for medication adherence solutions to overcome poor adherence to prescribed medication in the healthcare industry is projected to boost the demand for medication adherence solutions. According to a study published by The Journal of Allergy and Clinical Immunology, in Practice, there has been an increase in controller inhaler use between January and March 2020 by 14.5% where, Propeller Health, a digital platform that tracks the inhaler consumption was used to send alerts to the patients when it is missed. Non-adherence to medication increases cost urging the patients to use medication adherence to treat the problem effectively, thereby generating higher demand for medication adherence solutions. Major players in the medication adherence market report are Koninklijke Philips N.V., Cardinal Health Inc., Omnicell Inc., McKesson Corporation, Johnson & Johnson Services, Inc., Proteus Digital Health, Inc., AdhereTech Inc., Qualcomm Incorporated, Adherence Solutions LLC and SMRxT Inc. Inadequate healthcare infrastructure in developing countries is predicted to hinder the growth of the medication adherence market. In September 2021, according to a United Nations report, the health system in Afghanistan is in danger of collapsing, while on the streets of Kabul, the hunger that families are experiencing is just as severe there as it is in the country's drought-stricken rural districts. Moreover 9 out of 37 COVID-19 hospitals were closed. The poor infrastructure wedges the gap between the patient and the system restraining the growth of the medication adherence market. Major players are undertaking strategic initiatives such as partnerships and business expansions in untapped regions, which is likely to be a major trend in the medication adherence market. For instance, In December 2021, AdhereHealth, a US-based healthcare technology company specialising in medication adherence insights and health outcomes, partnered Hero. The partnership aimed at using Hero's digital in-home care platform to assist patients with chronic illnesses that have high costs, high risks, and complicated medication regimens. Hero is a medication adherence company that delivers end-to-end medication management service for patients and caregivers. In November 2021, CareDx, Inc., a US-based precision medicine company, acquired MedActionPlan for an undisclosed amount. The acquisition aimed to contribute to CareDx's mission of linking transplant patient offerings. MedActionPlan is a US-based company providing medication adherence services. North America was the largest region in the medication adherence market in 2022. Western Europe was the second largest region in the global medication adherence market share. The regions covered in the medication adherence industry analysis are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the medication adherence market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. Medication adherence market consists of sales of instruments such as smart pill bottles, smart caps, smart medical watches, wearable sensors and others. The market also includes technology associated applications such as cloud-based databases, health programs, patient web portals, mobile medication management applications and others. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The medication adherence market research report is one of a series of new reports from The Business Research Company that provides medication adherence market statistics, including medication adherence industry global market size, regional shares, competitors with a medication adherence market share, detailed medication adherence market segments, market trends and opportunities, and any further data you may need to thrive in the medication adherence industry. This medication adherence market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Medical lasers are devices that treat or remove tissues using precisely focused light sources. The main types of medical lasers are solid-state laser systems, gas laser systems, dye laser systems, and diode laser systems. A solid-state laser system is a laser system that uses a gain medium as a solid instead of liquid, as in dye lasers and gas as in gas lasers. The applications involved are surgical, cosmetic, and dental. The end-users involved are ophthalmology, dermatology, gynecology, dentistry, urology, cardiovascular, and others. The global medical lasers market is segmented - 1) By Product Type: Solid State Laser Systems, Gas Laser Systems, Dye Laser Systems, Diode Laser Systems 2) By Application: Surgical, Cosmetic, Dental 3) By End Use: Ophthalmology, Dermatology, Gynecology, Dentistry, Urology, Cardiovascular, Other End Users The global medical lasers market size grew from $5.56 billion in 2022 to $6.33 billion in 2023 at a compound annual growth rate (CAGR) of 13.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The medical lasers market is expected to grow from $10.45 billion in 2027 at a CAGR of 13.3%. The increased demand for minimally invasive procedures contributed to the medical lasers market’s growth during the period. The surge in aesthetic and cosmetic procedures propelled the demand for minimally invasive surgeries worldwide. According to the article published by Beautynews in April 2021, the number of facial plastic surgery procedures in the USA in 2020 is approximately 56,084, and the one was the brow lift procedure is nearly 31,404. Thus, the high usage of medical lasers to perform minimally invasive aesthetic and cosmetic surgeries increases the demand for medical lasers market. Major players in the medical lasers market are El.En. S.p.A, Ellex Medical Lasers Ltd., Lumenis, Alcon Laboratories Inc., AngioDynamics Corp., American Medical Systems Inc., Biolase Inc., Bausch & Lomb Holdings, Cardiogenesis Corporation Inc., and Boston Scientific. The high cost of surgeries limits the growth of the medical laser market. The high cost of treatments involving medical lasers limited the adoption and demand for lasers used to perform minimally invasive surgeries. For instance, the average cost of LASIK surgery performed in the USA was $1,500 per eye in 2021. Therefore, the high and increasing cost of surgeries is likely to act as a restraint to the growth of the medical lasers market. Major players operating in the market are focusing on developing new innovative products with advanced techniques to serve healthcare professionals and their patients better. For instance, in March 2021, Solta Medical, a division of Bausch Health, launched Clear + Brilliant Touch Laser. The new laser a more comprehensive treatment protocol by providing the benefits of two wavelengths and easing the treatment process. In October 2021, Laser MD Medspa, a US-based medical spa services company, acquired Young Medical Spa for an undisclosed amount. The acquisition would expand the company’s footprint in the state of Pennsylvania by adding four locations. Young Medical is a US-based provider of a full suite of cosmetic and aesthetic treatments, including laser hair removal, botox treatment, and others. North America was the largest region in the medical lasers market in 2022. Asia-Pacific was the second largest region in the global medical lasers market share. The regions covered in the global medical lasers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the medical lasers market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The medical lasers market consists of sales of solid-state laser systems, gas laser systems, dye laser systems, and diode laser systems. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The medical lasers market research report is one of a series of new reports from The Business Research Company that provides medical lasers market statistics, including medical lasers industry global market size, regional shares, competitors with a medical lasers market share, detailed medical lasers market segments, market trends and opportunities, and any further data you may need to thrive in the medical lasers industry. This medical lasers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The ophthalmology drugs market consists of sales of ophthalmology drugs and related services by entities (organizations, sole traders and partnerships) that produce ophthalmology drugs to treat eye related diseases. The ophthalmology drugs industry includes establishments that produce pharmaceutical drugs to treat glaucoma diseases, anti- inflammatory and tear stimulating drugs under dry eye medications drugs, and other drugs for treating retinal disorders and allergies. Some of the major ophthalmic drugs include Eylea, Lucentis, Restasis, Vigamox, Azopt, and Lotemax. The main types of ophthalmology drugs are antiglaucoma drugs, dry eye medication, and other ophthalmological drugs (retinal disorders, anti-infectives/allergy). Anti-glaucoma drugs are medications used to prevent or treat glaucoma, which is a disease in which the optic nerve is damaged, resulting in progressive, irreversible vision loss. The drugs are administered through oral, parenteral, and others that are classified into branded and generic drugs. The various mode of purchase includes prescription-based drugs and over-the-counter drugs which are distributed by hospital pharmacies, retail pharmacies/ drug stores and others. The global ophthalmology drugs market size is expected to grow from $50.62 billion in 2021 to $56.07 billion in 2022 at a compound annual growth rate (CAGR) of 10.8%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The ophthalmology drugs market is expected to reach $127.15 billion in 2026 at a CAGR of 22.7%. The expected rise in eye laser surgeries will contribute to the ophthalmology drugs market. Ophthalmology research has proved a link between laser eye surgeries and the prevalence of dry eye disorders. In an eye laser procedure, cutting of some nerves in the cornea leads to reduction in corneal sensitivity, in response to which, eyes may not sense the need for lubrication, causing the body to produce fewer tears. Dry eye is a common side effect after laser vision correction surgeries. It is estimated that almost half of the patients that undergo a laser surgery experience some degree of dry eye condition following the procedure. The number of eye laser procedures rose to 720,000 a year in 2020. A rising number of people going for laser eye surgeries is expected to increase the demand for dry eye medications in the forecast period driving the ophthalmology drugs market. Regulatory changes are likely to lead to increased costs relating to new product development and service offerings to clients. These changes are related to data protection such as the European Union's General Data Protection Regulation (GDPR), changes to drug approval procedures and other regulatory changes. For instance, according to a study on 100 Data Privacy and Data Security statistics for 2020, GDPR compliance is a top priority for 58% of European companies. The GDPR regulation is a EU law on data protection and privacy of individuals residing the European Union and the European Economic Area (EEA). It also regulates data anonymization thus maintaining integrity of data dealing with patients and other clinical trial studies. The potential loss of revenue due to delays in product release and additional costs incurred due to stringent approval processes puts strain to investments relating to new product development, thereby affecting the growth of the ophthalmology drugs market. Drug manufacturers are increasingly developing ophthalmic drugs with anti-inflammatory agents to ease patient treatment for dry eye syndrome. Anti-inflammatory drugs are widely used for the treatment of the inflammation produced by the dry eye syndrome, with the topical corticosteroid drops being the most common therapy. Corticosteroids can rapidly and effectively relieve the symptoms and signs of moderate or severe dry eye. However, prolonged usage of corticosteroids has seen to produce side effects that include risk of bacterial or fungal infection, elevated intraocular pressure and cataract formation. As a consequence, NSAIDs are increasingly being used as dry eye treatment instead of steroids to minimize the side effects. For instance, Aciex Therapeutics, a US-based pharmaceutical company, is developing NSAIDs which decrease ocular discomfort. Major companies in the ophthalmology drugs market include Regeneron Pharmaceuticals, Inc., Novartis AG, AbbVie, Santen Pharmaceutical Co., F. Hoffmann-La Roche Ltd., Bausch Health Companies Inc., Bayer AG, Sumitomo Chemical Co ltd, Mitsubishi Tanabe Pharma Corporation and Horizon Therapeutics plc. North America was the largest region in the ophthalmology drugs market in 2021. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the ophthalmology drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the ophthalmology drugs market report are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela and Vietnam. The global ophthalmology drugs market is segmented - 1) By Type: Antiglaucoma Drugs, Dry Eye Medication, Other Ophthalmological Drugs (Retinal Disorders, Anti-Infectives/Allergy) 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others 3) By Route of Administration: Oral, Parenteral, Others 4) By Drug Classification: Branded Drugs, Generic Drugs 5) By Mode of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs